Garry Nicholson

Garry Nicholson

Board Member

Garry Nicholson has more than 30 years of pharmaceutical and biotech oncology experience, including as the former president of Pfizer oncology where he led its global oncology franchise.

Mr. Nicholson currently serves as chairman of the board for G1 Therapeutics, and as a board member for Five Prime Therapeutics and Tmunity Therapeutics. He previously served on the TESARO board prior to its acquisition by GlaxoSmithKline. As president of Pfizer Oncology, his responsibilities included global commercialization, sales, clinical development, regulatory strategy and business development. Earlier in his career, he held various leadership positions in the oncology division of Eli Lilly and Company. He has also served as president and CEO of XTuit Pharmaceuticals. Mr. Nicholson earned a B.S. in Pharmacy from the University of North Carolina at Chapel Hill and an M.B.A. from the University of South Carolina.

Mr. Nicholson serves on the compensation and nominating and corporate governance committees.

Turning Point Therapeutics is now a
Bristol Myers Squibb company

Select OK for information about Turning Point Therapeutics.

Select BMS to learn more about Bristol Myers Squibb